Cyclacel Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1996-01-01
- Employees
- 12
- Market Cap
- -
- Website
- http://www.cyclacel.com
- Introduction
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05817890
- Locations
- 🇺🇸
Labcorp Clinical Research Unit, Madison, Wisconsin, United States
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 330
- Registration Number
- NCT05358379
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2021-12-23
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT05168904
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 330
- Registration Number
- NCT04983810
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT04017546
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
- Conditions
- AML, AdultMyelodysplastic SyndromesCML, RefractoryCLL, RefractoryALL, Adult
- Interventions
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03884829
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
- Conditions
- Relapsed or Refractory Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT03739554
- Locations
- 🇺🇸
Investigational Site, Houston, Texas, United States
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02552953
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 482
- Registration Number
- NCT01303796
- Locations
- 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Scripps Cancer Center, La Jolla, California, United States
🇺🇸UCLA Ronald Reagan Medical Center, Los Angeles, California, United States
Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2010-09-29
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT01211457
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States